SecurityOIA / Invesco Municipal Income Opportunities Trust (46132X101)
Institutional Owners49
Institutional Shares3,094,393
Institutional Value$ 129,899,000 USD

Institutional Stock Ownership and Shareholders

Invesco Municipal Income Opportunities Trust (NYSE:OIA) has 49 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,094,393 shares. Largest shareholders include Ameriprise Financial Inc, Morgan Stanley, Guggenheim Capital Llc, United Capital Financial Advisers, Llc, Wells Fargo & Company/mn, Raymond James Financial Services Advisors, Inc., Ladenburg Thalmann Financial Services Inc, Bokf, Na, Bank Of America Corp /de/, and UBS Group AG.
Invesco Municipal Income Opportunities Trust (NYSE:OIA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-01-13 13F-HR MetLife Securities, Inc 65,621 62,467 -4.81 544 448 -17.65
2018-05-14 13F-HR BOKF, NA 82,455 82,455 0.00 660 611 -7.42
2018-05-15 13F-HR Bank of New York Mellon Corp 17,841 0 -100.00 143 0 -100.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 1,000 1,000 0.00 8 7 -12.50
2018-05-15 13F-HR Advisor Group, Inc. 4,444 4,444 0.00 36 33 -8.33
2018-05-09 13F-HR LINCOLN NATIONAL CORP 13,780 0 -100.00 110 0 -100.00
2018-05-15 13F-HR UNITED CAPITAL FINANCIAL ADVISERS, LLC 191,945 233,577 21.69 1,536 1,731 12.70
2018-05-09 13F-HR IFP Advisors, Inc 32,074 31,706 -1.15 257 235 -8.56
2018-05-03 13F-HR BANK OF HAWAII 13,403 13,403 0.00 107 99 -7.48
2018-05-14 13F-HR MORGAN STANLEY 459,965 444,925 -3.27 3,680 3,297 -10.41
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 22,738 25,965 14.19 176 205 16.48
2018-04-18 13F-HR Creative Planning 0 28,323 0 210
2018-05-14 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 760 807 6.18 6 6 0.00
2018-05-15 13F-HR Krilogy Financial LLC 131 121 -7.63
2018-04-04 13F-HR DAVENPORT & Co LLC 12,289 12,289 0.00 98,312 91,061 -7.38
2018-04-24 13F-HR Rehmann Capital Advisory Group 11,118 11,118 0.00 89 82 -7.87
2018-05-07 13F-HR Arlington Partners Llc 2,150 16
2018-05-15 13F-HR Invesco Ltd. 116,676 79,749 -31.65 933 591 -36.66
2018-05-15 13F-HR LPL Financial LLC 13,688 32,506 137.48 110 241 119.09
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 26,697 26,813 0.43 214 198 -7.48
2018-05-11 13F-HR VAN ECK ASSOCIATES CORP 74,188 73,194 -1.34 594 542 -8.75
2018-05-15 13F-HR UBS Group AG 86,630 80,457 -7.13 693 596 -14.00
2018-05-14 13F-HR BB&T SECURITIES, LLC 10,178 75
2018-04-16 13F-HR Capital Investment Advisors, LLC 61,851 61,851 0.00 495 458 -7.47
2018-04-20 13F-HR Seacrest Wealth Management, Llc 2,287 2,287 0.00 18 17 -5.56
2018-05-25 13F-HR/A SUNTRUST BANKS INC 10,023 0 -100.00 68 0 -100.00
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 587,132 586,840 -0.05 4,697 4,346 -7.47
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 95,394 97,827 2.55 763 725 -4.98
2018-04-23 13F-HR Kiley Juergens Wealth Management, Llc 3,000 0 -100.00 24 0 -100.00
2018-05-15 13F-HR HighTower Advisors, LLC 44,806 44,806 0.00 358 332 -7.26
2018-05-11 13F-HR CITIGROUP INC 2,500 2,500 0.00 20 19 -5.00
2018-05-09 13F-HR Cambridge Investment Research Advisors, Inc. 15,948 15,948 0.00 128 118 -7.81
2018-04-26 13F-HR Winslow, Evans & Crocker, Inc. 2,146 2,146 0.00 17,168 15,902 -7.37
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 169,912 154,269 -9.21 1,359 1,142 -15.97
2018-05-11 13F-HR First Allied Advisory Services, Inc. 17,738 17,738 0.00 142 132 -7.04
2018-04-05 13F-HR RAYMOND JAMES TRUST N.A. 13,212 13,212 0.00 106 98 -7.55
2018-05-14 13F-HR Camelot Portfolios, LLC 33,886 33,886 0.00 271 251 -7.38
2018-04-19 13F-HR Endurance Wealth Management, Inc. 28 28 0.00 0 0
2018-05-15 13F-HR FIFTH THIRD BANCORP 4,577 15,383 236.09 37 114 208.11
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 5,515 7,515 36.26 44 56 27.27
2018-05-11 13F-HR MML INVESTORS SERVICES, LLC 55,938 56,621 1.22 448 420 -6.25
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 55,664 40,303 -27.60 445 299 -32.81
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 33,227 36,200 8.95 266 268 0.75
2018-05-03 13F-HR Bedel Financial Consulting, Inc. 4,303 32
2018-04-24 13F-HR Allegis Investment Advisors, LLC 22,105 22,105 0.00 177 164 -7.34
2018-04-20 13F-HR FIRST MANHATTAN CO 3,173 3,173 0.00 25 23 -8.00
2018-05-15 13F-HR HONKAMP KRUEGER FINANCIAL SERVICES INC /ADV 656 5
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 414,212 363,369 -12.27 3,314 2,693 -18.74
2018-05-03 13F-HR Partnervest Advisory Services LLC 10,315 10,315 0.00 83 76 -8.43
2018-04-27 13F-HR Barrett Asset Management, LLC 5,200 0 -100.00 42 0 -100.00
2018-05-11 13F-HR SEI INVESTMENTS CO 593 4
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. 157,713 143,090 -9.27 1,262 1,060 -16.01
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 91,302 81,783 -10.43 731 606 -17.10
2018-05-09 13F-HR Cetera Advisor Networks LLC 152,713 0 -100.00 1,222 0 -100.00
2018-05-11 13F-HR Private Ocean, LLC 18,120 134
2018-05-08 13F-HR US BANCORP \DE\ 4,036 0 -100.00 32 0 -100.00

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 46132X101